InvestorsHub Logo
Followers 239
Posts 12003
Boards Moderated 0
Alias Born 08/14/2003

Re: stockzillla post# 104532

Thursday, 07/20/2017 5:53:20 PM

Thursday, July 20, 2017 5:53:20 PM

Post# of 203907
I just checked, in case their was some change, but the Clinical Trials site for the trial still hasn't been updated. I would think that when the trial ends, the company at the least would update the data indicating that is the case.

Here's a link:

https://clinicaltrials.gov/ct2/show/NCT02976779?term=Psoriasis+Cream&draw=1&rank=1

I know someone was told that the trial wasn't being done in the U.S. so they hadn't said it was enrolling participants here, but other companies in similar circumstances do update the database. We know the trial went through IRB approval and enrollment in Israel's Sheba Hospital should have been completed some time ago, but I don't remember being told this officially.

For those who allege that the company issues PR's to boost the stock price, this certainly seems like an opportunity that completely slipped through their hands. I've seen companies issue PR's when the first patient entered a trial, then again, when the last patient was enrolled, then when the clinical portion of the trial completed, and finally they released and discussed the results. In short, their were many opportunities here, and the company did not take one of them. Not exactly the hype some here accuses the company of.

Truthfully, most big Pharma's say nothing about Phase 1 Trials, but tiny Biotech's often do. Trials generally get more interest as they go into Phase 2 and 3. The reality is, this drug may not require true Phase 2 or 3 Trials, but Mediq seems to be proposing further trials which will probably be categorized as Phase 2 for record keeping purposes.

Gary